U.S. Human Chorionic Gonadotropin (HCG) Market Revenue to Attain USD 820 Mn by 2033

23 Dec 2024

Share :

Table of Content

1. U.S. Human Chorionic Gonadotropin (HCG) Market Revenue and Trends 2023 to 2033 2. Market Overview  3. Report Highlights of the U.S. Human Chorionic Gonadotropin (HCG) Market  4. Major Trends¯in the U.S. Human Chorionic Gonadotropin (HCG) Market   5. U.S. Human Chorionic Gonadotropin (HCG) Market Coverage 6. Market News 7. U.S. Human Chorionic Gonadotropin (HCG) Market Key Players

U.S. Human Chorionic Gonadotropin (HCG) Market Revenue and Trends 2023 to 2033

The global U.S. human chorionic gonadotropin (HCG) market revenue reached USD 620 million in 2024 and is predicted to attain around USD 820 million by 2033 with a CAGR of 3.34%. The rapid expansion of fertility clinics and the increasing demand for fertility treatments boost market growth.

Market Overview 

Human chorionic gonadotropin (HCG), commonly referred to as the pregnancy hormone, plays a crucial role in sustaining pregnancy. It is produced by the placenta shortly after the embryo attaches to the uterine lining, marking the beginning of pregnancy. One of the primary functions of HCG is to stimulate the ovaries to produce estrogen and progesterone. These hormones are vital for creating a supportive environment in the uterus by thickening the uterine lining, which is essential for the implantation and nourishment of the developing embryo. During the early stages of pregnancy, particularly throughout the first trimester, HCG levels rise steadily. This increase can typically be detected in both blood and urine tests, providing a reliable method for confirming pregnancy. The measuring of HCG levels is instrumental not only in confirming pregnancy but also in monitoring its progress, as abnormal HCG levels can indicate potential complications.

Beyond its role in pregnancy, HCG is also utilized in various medical applications. For instance, it serves as a tumor marker for certain germ cell tumors, helping healthcare providers monitor treatment effectiveness and disease progression. Additionally, HCG is employed in fertility treatments, where it can induce ovulation and support the establishment of pregnancy in individuals facing infertility challenges. These diverse applications underscore HCG's significance in reproductive health and clinical diagnostics. The market is experiencing rapid growth due to the growing infertility rate and the rising demand for assisted reproductive technologies.

Report Highlights of the U.S. Human Chorionic Gonadotropin (HCG) Market 

• Based on product type, the native human chorionic gonadotropin segment registered dominance in the market in 2023, as it plays an essential role in enhancing ovulatory function during pregnancy. The placenta produces this hormone since it thickens a person's uterine lining to support a growing embryo and gears the body to stop menstruation. This hormone is created in urine or blood during the period of 10 to 11 days after conception, and medical professionals also confirm and measure pregnancy progress through native HCG. On the other hand, the recombinant human chorionic gonadotropin segment is anticipated to grow rapidly in the coming years. Recombinant HCG is widely used for different purposes in men and women. The main therapeutic uses of recombinant HCG are in the treatment of anovulatory infertility and male infertility related to hypogonadism caused by reduced gonadotrophin secretion. An injectable formulation of human chorionic gonadotropin is also prepared using recombinant DNA technology. The injection is used to induce ovulation induction and pregnancy in anovulatory patients, and the formulation is also used to trigger ovulation and time intercourse in combination with ovulation induction.
• By therapeutic area, the female infertility treatment segment led the U.S. human chorionic gonadotropin (HCG) market in 2023. This is mainly due to the increasing infertility rates in females. Female infertility can be caused due to abnormalities in the uterus, ovaries, and the endocrine system. Fertility can be restored in two ways, that is, medication or surgery. There are different types of drugs, such as clomiphene citrate, gonadotropins, metformin, letrozole, and bromocriptine, that are used to regulate or stimulate ovulation. However, the male hypogonadism segment is projected to expand at a high CAGR during the forecast period. Male hypogonadism is a condition in which a patient faces a testosterone deficiency, a hormone that plays a crucial role in maintaining sexual, cognitive, and body function and development. The HCG injections cure leading issues due to low testosterone levels and other abnormalities.
• On the basis of distribution channel, the hospital pharmacies segment dominated the market in 2023. This is primarily due to the easy availability of prescription products. Hospital pharmacies are open 24/7 since they are situated inside the hospital, which gives them an advantage over other pharmacies. They also refund unused medications when returned to them.

Major Trends¯in the U.S. Human Chorionic Gonadotropin (HCG) Market  

• Rising Demand for Fertility Treatments: With the increasing infertility rates due to unhealthy eating habits and inactive lifestyles, there is a high demand for fertility treatments among women. Moreover, growing awareness about the availability of infertility treatments boosts market growth. 
• Technological Advancements: Advancements in technology led to the development of fetal health monitoring devices, which play a crucial role in enhancing maternal and fetal well-being by actively detecting and mitigating the risk of complications throughout the pregnancy period. For instance, cardiotocography measures pregnancy contractions and fetal heart rates, allowing medical professionals to diagnose any potential complications early on. These innovative devices utilize sophisticated technologies such as sensors and algorithms to monitor vital parameters, including fetal heart rate, uterine activity, and maternal health indicators. By providing real-time data and alerts to healthcare providers and parents, these tools help identify potential issues, facilitating timely interventions. As a result, the increased emphasis on effective prenatal care through these monitoring solutions significantly contributes to the market's overall growth. 
• Integration of AI: Integrating AI solutions in infertility treatments represents a significant advancement in the field of maternal healthcare. Several startups are emerging with AI-based technologies designed to gather comprehensive data related to maternal health. These solutions not only monitor various health metrics but also provide real-time insights and alerts to healthcare providers and expectant mothers. By leveraging this data, they aim to raise awareness about the importance of maternal healthcare, enabling proactive measures and personalized care options. This approach is transforming how maternal health information is accessed and utilized, ultimately leading to improved health outcomes for mothers and their infants.
• Demand for Non-invasive Tests: Non-invasive testing is in high demand, as it can detect birth defects and genetic diseases without risking the fetus compared to prenatal tests. For instance, a US-based startup, Mirvie, creates non-invasive molecular diagnostic tests for fetuses.

U.S. Human Chorionic Gonadotropin (HCG) Market Coverage

Market News

• In May 2024, Apotex Corp. announced the launch of Cetrorelix Acetate for Injection 0.25mg, a generic version of Cetrotide in the U.S. Cetrorelix Acetate for Injection is a synthetic decapeptide with gonadotrophin-releasing hormone (GnRH) antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

U.S. Human Chorionic Gonadotropin (HCG) Market Key Players

• Aspen API
• Livzon Pharmaceuticals
• Lupin
• Merck & Co., Inc.
• Scripps Laboratories
• Shanghai Techwell Biopharmaceutical Co. Ltd.
• Sun Pharmaceuticals Ltd.
• Zydus Lifesciences Ltd.
• Merck Serono
• Ningbo Renjian Pharmaceutical Group Co. Ltd.
• Sanzyme
• Ferring Pharmaceuticals
• Fresenius Kabi

Market Segmentation

By Product Type

• Native Human Chorionic Gonadotropin
• Recombinant Human Chorionic Gonadotropin

By Therapeutic Area

• Female Infertility Treatment
• Male Hypogonadism
• Oligospermic Treatment
• Cryptorchidism Treatment
• Chronic Pain
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344